Paper35802255
Mavacamten: First Approval.
Keam SJ. Drugs, 2022. Cited by 79 papers, by iCite.
Cite this record
ConductScience Library. Mavacamten: First Approval. Papers, record 35802255. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35802255
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Benzylamines | Major topic |
| Cardiomyopathy, Hypertrophic | Major topic |
| Adult | |
| Cardiac Myosins | |
| Humans | |
| Uracil |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Erratum in | 35921035 | Correction to: Mavacamten: First Approval. | https://conductscience.org/library/papers/35921035 |
Source PubMed
References2
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30428294 | Clinical Course and Management of Hypertrophic Cardiomyopathy. | N Engl J Med | 2018 | https://conductscience.org/library/papers/30428294 | PubMed |
| 2 | 35435607 | The Impact of Mavacamten on the Pathophysiology of Hypertrophic Cardiomyopathy: A Narrative Review. | Am J Cardiovasc Drugs | 2022 | https://conductscience.org/library/papers/35435607 | PubMed |
Cited by52
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 79 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42911542 | Real-World Effectiveness of Mavacamten in Canada: Insights from the MAVEN Study. | Cardiol Ther | 2026 | https://conductscience.org/library/papers/42911542 | PubMed |
| 42405364 | Comprehensive Framework of Heart Failure with Preserved Ejection Fraction Management for Hospitalists: A Scoping Review. | J Brown Hosp Med | 2026 | https://conductscience.org/library/papers/42405364 | PubMed |
| 42327436 | Early Insights on Mavacamten Usage in Canada: A Retrospective Cohort Study of the Mavacamten Patient Support Program. | CJC Open | 2026 | https://conductscience.org/library/papers/42327436 | PubMed |
| 42160017 | Safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of HRS-1893, a cardiac myosin inhibitor, in healthy subjects. | Br J Clin Pharmacol | 2026 | https://conductscience.org/library/papers/42160017 | PubMed |
| 41941083 | Aficamten: First Approval. | Drugs | 2026 | https://conductscience.org/library/papers/41941083 | PubMed |
| 41641607 | Efficacy and Safety of Mavacamten and Aficamten in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis. | Crit Pathw Cardiol | 2026 | https://conductscience.org/library/papers/41641607 | PubMed |
| 41375897 | Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Targeting Sarcomeric Hypercontractility with Demonstrated Long-Term Safety and Efficacy-A Narrative Review. | J Clin Med | 2025 | https://conductscience.org/library/papers/41375897 | PubMed |
| 41174905 | Editorial: Hypertrophic Cardiomyopathy and Precision Medicine in Cardiovascular Disease. | Med Sci Monit | 2025 | https://conductscience.org/library/papers/41174905 | PubMed |
| 41043917 | Cardiogenic Shock in Hypertrophic Cardiomyopathy Treated With Mavacamten and Clarithromycin. | JACC Case Rep | 2025 | https://conductscience.org/library/papers/41043917 | PubMed |
| 40867543 | Cardiac Myosin Inhibitors in the Treatment of Hypertrophic Cardiomyopathy: Clinical Trials and Future Challenges. | Biomolecules | 2025 | https://conductscience.org/library/papers/40867543 | PubMed |
| 40852491 | Early Detection of Treatment Response to Mavacamten in Hypertrophic Obstructive Cardiomyopathy With Severe Mitral Regurgitation Using Magnetocardiography. | Clin Case Rep | 2025 | https://conductscience.org/library/papers/40852491 | PubMed |
| 40708763 | A Systematic Review of Clinical Trials on Mavacamten in Hypertrophic Cardiomyopathy. | Heart Int | 2025 | https://conductscience.org/library/papers/40708763 | PubMed |
| 40624601 | Cardiac myosin inhibitors in hypertrophic cardiomyopathy. | J Cardiovasc Imaging | 2025 | https://conductscience.org/library/papers/40624601 | PubMed |
| 40515800 | Unveiling the complexity of nonobstructive hypertrophic cardiomyopathy. | Heart Fail Rev | 2025 | https://conductscience.org/library/papers/40515800 | PubMed |
| 40500110 | Cardiac myosin inhibitors: a silver lining for an old disease. | Open Heart | 2025 | https://conductscience.org/library/papers/40500110 | PubMed |
| 40488145 | Reduction in myofilament Ca2+ sensitivity partially ameliorates the cardiac phenotype in hypertrophic cardiomyopathy linked to a TnT-R92Q mutation. | Front Physiol | 2025 | https://conductscience.org/library/papers/40488145 | PubMed |
| 40400802 | Mavacamten Cardiac Myosin Inhibitor: Clinical Applications and Future Perspectives. | Cureus | 2025 | https://conductscience.org/library/papers/40400802 | PubMed |
| 40306862 | Experimental Models of Hypertrophic Cardiomyopathy: A Systematic Review. | JACC Basic Transl Sci | 2025 | https://conductscience.org/library/papers/40306862 | PubMed |
| 40246577 | Tale of three services: early UK experience with mavacamten treatment for hypertrophic cardiomyopathy with left ventricular outflow tract obstruction. | Open Heart | 2025 | https://conductscience.org/library/papers/40246577 | PubMed |
| 40169351 | Real-World Experience of Mavacamten for Patients With Obstructive Hypertrophic Cardiomyopathy in South Korea: A Prospective Multi-Center Observational Study. | Korean Circ J | 2025 | https://conductscience.org/library/papers/40169351 | PubMed |
Genes14
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35802255
GET https://conductscience.org/api/papers/v1/35802255/cited_by?page=2